AAAAAA
Results:
1-11
|
Results: 11
Authors:
Herling, M
Rassidakis, GZ
Viviani, S
Bonfante, V
Giardini, R
Gianni, M
Morris, SW
Cabanillas, F
Medeiros, LJ
Sarris, AH
Citation: M. Herling et al., Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: Results with ALK-11 antibody in 327 untreated patients, LEUK LYMPH, 42(5), 2001, pp. 969
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease
Authors:
Bonfante, V
Viviani, S
Devizzi, L
Di Russo, A
Di Nicola, M
Magni, M
Matteucci, P
Grisanti, S
Valagussa, P
Bonadonna, G
Gianni, AM
Citation: V. Bonfante et al., High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease, EUR J HAEMA, 66, 2001, pp. 51-55
Authors:
Lissoni, P
Malugani, F
Bonfanti, A
Bucovec, R
Secondino, S
Brivio, F
Ferrari-Bravo, A
Ferrante, R
Vigore, L
Rovelli, F
Mandala, M
Viviani, S
Fumagalli, L
Gardani, GS
Citation: P. Lissoni et al., Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulatingdendritic cells, IL-12 and endothelin-1, J BIOL REG, 15(2), 2001, pp. 140-144
Authors:
Di Russo, A
Villani, F
Soncini, F
Catania, AF
Viola, G
Vismara, C
Viviani, S
Bonfante, V
Citation: A. Di Russo et al., Lung function and serum levels of different cytokines in patients treated with intermediate-high dose chemotherapy and radiotherapy involved fields for advanced stage Hodgkin's disease, TUMORI, 87(4), 2001, pp. S121-S121
Authors:
Viviani, S
Notti, P
Bonfante, V
Verderio, P
Valagussa, P
Bonadonna, G
Citation: S. Viviani et al., Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute Experience, MED ONCOL, 17(1), 2000, pp. 59-63
Authors:
Santoro, A
Bredenfeld, H
Devizzi, L
Tesch, H
Bonfante, V
Viviani, S
Fielder, F
Parra, HS
Benoehr, C
Pacini, M
Bonadonna, G
Diehl, V
Citation: A. Santoro et al., Gemcitabine in the treatment of refractory Hodgkins's disease: Results of a multicenter phase II study, J CL ONCOL, 18(13), 2000, pp. 2615-2619
Authors:
Villani, F
Viviani, S
Bonfante, V
De Maria, P
Soncini, F
Laffranchi, A
Citation: F. Villani et al., Late pulmonary effects in favorable stage I and IIA Hodgkin's disease treated with radiotherapy alone, AM J CL ONC, 23(1), 2000, pp. 18-21
Authors:
Viviani, S
Bonfante, V
Santoro, A
Zanini, M
Devizzi, L
Di Russo, A
Soncini, F
Villani, F
Ragni, G
Valagussa, P
Bonadonna, G
Citation: S. Viviani et al., Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease, CA J SCI AM, 5(5), 1999, pp. 275-282
Authors:
Lissoni, P
Brivio, F
Viviani, S
Fumagalli, L
Citation: P. Lissoni et al., Which immunological parameters ave clinically essential to monitor IL-2 cancer immunotherapy?, J BIOL REG, 13(2), 1999, pp. 110-114
Authors:
Viviani, S
Jack, A
Hall, AJ
Maine, N
Mendy, M
Montesano, R
Whittle, HC
Citation: S. Viviani et al., Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age, VACCINE, 17(23-24), 1999, pp. 2946-2950
Authors:
Villani, F
Dell'Oca, I
De Maria, P
Viola, G
Di Russo, A
Viviani, S
Bonfante, V
Citation: F. Villani et al., Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease, ANTICANC R, 19(5C), 1999, pp. 4475-4479
Risultati:
1-11
|